The Top 5 Biosimilars Articles for the Week of November 27

The Center for Biosimilars Staff

The Center for Biosimilars recaps the top 5 articles for the week of November 27.

Transcript:

Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of November 27.

Number 5: The World Health Organization has a released a new report that estimates that 1 in 10 drugs worldwide is either falsified or substandard, leading to unnecessary deaths and increased costs to patients and health systems.

Number 4: German drug maker Formycon projects that its biosimilar challenger to Lucentis will be launched in the US market in 2020.

Number 3: The FDA has begun to add 4-letter suffixes, devoid of meaning, to the nonproprietary names of newly approved biologics.

Number 2: Contributor Brian Lehman explains the potential impact of CMS’ proposed rule that would treat biosimilars as generic drugs for the purpose of cost-sharing under Medicare Part D.

Number 1: The FDA has approved Mylan and Biocon’s trastuzumab biosimilar, referenced on Herceptin.

Finally, last week, our e-newsletter asked whether you think that innovative device design will play a role in reference product sponsors’ defense strategies against biosimilar competition. To see results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.